Loading
Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.
Hervé Tilly (Rouen) was principal investigator and first author of POLARIX, which showed replacing vincristine with the CD79b ADC polatuzumab vedotin in R-CHOP reduces progression or death by 27% in previously untreated DLBCL. He has led LYSA trials for decades, including LNH03-6B in older patients, and chaired the ESMO DLBCL guidelines.
Shares POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma, POLARIX, LYSA (The Lymphoma Study Association), CD20 and the tags lymphoma, lysa.
Shares POLARIX, CD20, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma and the tag lymphoma.
Shares LYSA (The Lymphoma Study Association), Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD20, Diffuse large B-cell lymphoma and the tags lymphoma, lysa.
Shares Antibody-drug conjugate (ADC) and the tags lymphoma, adc.
Shares POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma, POLARIX, CD20, Antibody-drug conjugate (ADC).
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma, POLARIX, CD20, Antibody-drug conjugate (ADC).